MA55857A - Formes posologiques solides pharmaceutiques ou nutraceutiques multicouches comprenant des dérivés de pyrimidine et/ou de purine et des vitamines b, leur préparation et leurs utilisations - Google Patents

Formes posologiques solides pharmaceutiques ou nutraceutiques multicouches comprenant des dérivés de pyrimidine et/ou de purine et des vitamines b, leur préparation et leurs utilisations

Info

Publication number
MA55857A
MA55857A MA055857A MA55857A MA55857A MA 55857 A MA55857 A MA 55857A MA 055857 A MA055857 A MA 055857A MA 55857 A MA55857 A MA 55857A MA 55857 A MA55857 A MA 55857A
Authority
MA
Morocco
Prior art keywords
nutraceutic
vitamins
pyrimidine
preparation
dosage forms
Prior art date
Application number
MA055857A
Other languages
English (en)
Inventor
Mollar Berta Fernández
Sáiz Pablo Martín
Original Assignee
Ferrer Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferrer Int filed Critical Ferrer Int
Publication of MA55857A publication Critical patent/MA55857A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA055857A 2019-05-06 2019-11-06 Formes posologiques solides pharmaceutiques ou nutraceutiques multicouches comprenant des dérivés de pyrimidine et/ou de purine et des vitamines b, leur préparation et leurs utilisations MA55857A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19382340 2019-05-06

Publications (1)

Publication Number Publication Date
MA55857A true MA55857A (fr) 2022-03-16

Family

ID=66529933

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055857A MA55857A (fr) 2019-05-06 2019-11-06 Formes posologiques solides pharmaceutiques ou nutraceutiques multicouches comprenant des dérivés de pyrimidine et/ou de purine et des vitamines b, leur préparation et leurs utilisations

Country Status (22)

Country Link
US (1) US12533371B2 (fr)
EP (1) EP3965744B1 (fr)
JP (1) JP2022531663A (fr)
KR (1) KR20220005024A (fr)
CN (1) CN113784706B (fr)
AU (1) AU2019444412B2 (fr)
BR (1) BR112021021769A2 (fr)
CA (1) CA3137221A1 (fr)
CL (1) CL2021002874A1 (fr)
CO (1) CO2021015353A2 (fr)
DO (1) DOP2021000225A (fr)
EA (1) EA202193041A1 (fr)
EC (1) ECSP21080548A (fr)
JO (1) JOP20210296A1 (fr)
MA (1) MA55857A (fr)
MX (1) MX2021013565A (fr)
PE (1) PE20220498A1 (fr)
PH (1) PH12021552618A1 (fr)
SG (1) SG11202111084WA (fr)
TW (1) TWI827736B (fr)
UA (1) UA127913C2 (fr)
WO (1) WO2020224795A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250175556A (ko) 2024-06-10 2025-12-17 최종배 제3자 개입을 통한 보이스 피싱 예방 방법
KR20250179027A (ko) 2024-06-20 2025-12-29 제이제이소프트 주식회사 본인인증정보 관리 및 이를 통한 금융사기 방지 방법

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA995133A (en) * 1973-03-29 1976-08-17 Shunkichi Tamura Uridine-5'-monophosphate compositions
GB1363398A (en) * 1973-03-29 1974-08-14 Yamasa Shoyu Kk Uridine-5.-monophosphate compositions
AU587863B2 (en) * 1985-10-07 1989-08-31 Basf Aktiengesellschaft Vitamin-containing granules and production thereof
JPH01308232A (ja) * 1988-06-03 1989-12-12 Takeda Chem Ind Ltd 固型医薬およびその製造法
JPH05194275A (ja) * 1991-09-03 1993-08-03 Takeda Chem Ind Ltd 製剤用組成物、固形製剤および薬物の防臭方法
CA2110313C (fr) 1992-12-01 2004-10-26 Edward John Roche Compositions pharmaceutiques contenant un compose de guanidothiazole et antiacides
DE10215753A1 (de) 2002-04-10 2003-10-30 Trommsdorff Arzneimittel Verwendung von Pyrimidinnukleotiden zur Behandlung von Schädigungen des peripheren Nervensystems
AR051950A1 (es) 2004-11-10 2007-02-21 Osmotica Pharmaceutical Argent Comprimido multicapa con capas que se separan
JP4775879B2 (ja) * 2004-11-17 2011-09-21 塩野義製薬株式会社 ビタミン組成物
CN101184496A (zh) * 2005-05-27 2008-05-21 兴和株式会社 用于恢复疲劳的药品
US7638142B2 (en) * 2005-10-12 2009-12-29 Vitamin Science, Inc. Therapeutic composition for the treatment of dry eye syndrome
KR100870104B1 (ko) * 2005-11-28 2008-11-26 주식회사 머젠스 안구건조증 치료 및 예방용 조성물
KR100869444B1 (ko) 2007-07-11 2008-11-18 주식회사 중외제약 유비데카레논을 함유하는 다층정 비타민 복합제제
WO2012091542A1 (fr) * 2010-12-28 2012-07-05 N.V. Nutricia Combinaison de composants destinée à prévenir et traiter la fragilité
WO2012125020A1 (fr) 2011-03-14 2012-09-20 N.V. Nutricia Méthode de traitement d'un traumatisme neurologique
WO2016148561A1 (fr) * 2015-03-16 2016-09-22 N.V. Nutricia Procédé d'amélioration de la fonction vésicale
US11291683B2 (en) * 2016-04-01 2022-04-05 Access Business Group International Llc Bilayer tablets of B vitamins and process for preparing the same
MX391725B (es) * 2016-04-21 2025-03-21 Astrocyte Pharmaceuticals Inc Compuestos y metodos para tratamiento de afecciones neurologicas y cardiovasculares.
EP3366291A1 (fr) 2017-02-22 2018-08-29 Montero Gida Sanayi Ve Ticaret A.S. Compositions pharmaceutiques orales solides comprenant de l'acide lipoïque alpha et des vitamines solubles dans l'eau

Also Published As

Publication number Publication date
CA3137221A1 (fr) 2020-11-12
JOP20210296A1 (ar) 2023-01-30
WO2020224795A1 (fr) 2020-11-12
BR112021021769A2 (pt) 2021-12-28
TW202108132A (zh) 2021-03-01
ECSP21080548A (es) 2022-02-25
US20220160744A1 (en) 2022-05-26
PH12021552618A1 (en) 2022-07-18
MX2021013565A (es) 2022-01-04
EP3965744C0 (fr) 2025-12-31
TWI827736B (zh) 2024-01-01
EP3965744A1 (fr) 2022-03-16
CL2021002874A1 (es) 2022-06-17
EA202193041A1 (ru) 2022-02-10
KR20220005024A (ko) 2022-01-12
JP2022531663A (ja) 2022-07-08
PE20220498A1 (es) 2022-04-07
CN113784706A (zh) 2021-12-10
UA127913C2 (uk) 2024-02-07
DOP2021000225A (es) 2022-03-15
AU2019444412B2 (en) 2025-02-20
CO2021015353A2 (es) 2021-11-19
US12533371B2 (en) 2026-01-27
EP3965744B1 (fr) 2025-12-31
AU2019444412A1 (en) 2021-11-04
SG11202111084WA (en) 2021-11-29
CN113784706B (zh) 2024-01-05

Similar Documents

Publication Publication Date Title
Tsukihara et al. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts
MA38399B2 (fr) Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique
EP3978029A4 (fr) Acide nucléique, composition et conjugué pharmaceutiques, leur procédé de préparation et leur utilisation
HRP20240231T1 (hr) Farmaceutske formulacije inhibitora brutonove tirozin kinaze
WO2016196776A3 (fr) Inhibiteurs de la tyrosine kinase de bruton
EA201100032A1 (ru) Соединения пиридина
BR112018006817A2 (pt) método de tratamento do câncer
IL284930A (en) History of pyrrolopyrimidines and their use in the treatment of protein kinase-related diseases
Mustafa et al. Varicella zoster virus: review of its management
MY152540A (en) Powder formulation for valganciclovir
MA55857A (fr) Formes posologiques solides pharmaceutiques ou nutraceutiques multicouches comprenant des dérivés de pyrimidine et/ou de purine et des vitamines b, leur préparation et leurs utilisations
MA45625A (fr) Nouveaux régimes posologiques pour conjugués anticorps-médicaments à base d'anticorps anti-axl
Giacalone et al. Improving bioavailability and biodistribution of anti-HIV chemotherapy
JP2016501222A5 (fr)
BRPI0715609A2 (pt) Composto, uso de um composto, métodos para produzir um efeito antiproliferativo em um animal de sangue quente, e para tratar uma doença em um animal de sangue quente, e, composição farmacêutica
BR112019005214A2 (pt) composição farmacêutica compreendendo antagonista do receptor de mineralocorticoide e uso da mesma
MX391191B (es) Composiciones de liberación extendida de onapristona y métodos.
EP3431107A4 (fr) Particules de composition pharmaceutique et préparation se délitant par voie orale comprenant celles-ci
BR112016002194A2 (pt) “potencialização do efeito do metotrexato por meio do uso combinado com estatinas lipofílicas”
EP3814340A4 (fr) Nouveaux dérivés de catéchol ou sel de ceux-ci, leurs procédés de préparation et compositions pharmaceutiques les comprenant
HK1218861A1 (zh) 包含异烟肼颗粒和利福喷汀颗粒的呈可分散的片剂形式的抗结核病的稳定的药物组合物及其制备方法
WO2017067664A9 (fr) Composés oxa-diazaspiro ayant une activité contre la douleur
Qin et al. Reply to S. Zhang, L. Fornaro et al, and HJ Lee et al
ZHAO et al. Clinical study of iguratimod in the treatment of active rheumatoid arthritis
EP3870167A4 (fr) Compositions pharmaceutiques et procédés de préparation de formulations posologiques solides à la demande